Generated by AI
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 2's posts. Generated by AI.
Summary of Feb 24's posts. Generated by AI.
Summary of Oct 28's posts. Generated by AI.
Investors talking about VNDA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.
Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on developing and commercializing therapies for high unmet medical needs. Its current portfolio centers on treatments for sleep-wake disorders, schizophrenia, and other central nervous system conditions, supported by a selective pipeline that includes additional clinical and preclinical programs. The company’s marketed products include HETLIOZ and Fanapt, while PONVORY adds a presence in immune-related therapeutics. Vanda also works on specialty medicines for rare diseases and other targeted indications, using genetics and genomics to guide drug discovery and clinical development. With a concentrated product mix and a research-driven model, Vanda Pharmaceuticals Inc. plays a specialized role in the biopharmaceutical market by addressing niche patient populations where treatment options may be limited.
Website2200 Pennsylvania Avenue NW
Washington, DC, 20037
United States
The latest articles about VNDA.
Anthropic is gearing up for a blockbuster initial public offering this week, and excitement among retail investors looks to be off the charts.